Abstract
A novel class of therapeutic agents based on nucleic acids has emerged and shown very promising pre-clinical results, named small interfering RNAs (siRNAs) and microRNAs (miRNAs). siRNAs are small RNA duplexes capable of silencing undesired (i.e., mutant, exogenous or aberrant) gene expression with high specificity through a mechanism known as RNA interference. These agents have called special attention to neuroscience since they have been used to experimentally treat a variety of neurological diseases with distinct etiologies such as viral, prions, genetic disorders and others. siRNAs have also been used in other scenarios as: drug-receptor blockage, inhibition of pain signaling and regulation of behavior. Although in a very initial stage, miRNAs also promise novel therapeutic approaches. In this review article we intend to introduce clinicians and researchers to the novel field of si- and miRNA-mediated gene silencing strategies, its history, use in cell and animal models, delivery methods, current status and possible applications in future clinical practice.
Central Nervous System Agents in Medicinal Chemistry
Title: Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Volume: 8 Issue: 2
Author(s): Tiago Campos Pereira and Iscia Lopes-Cendes
Affiliation:
Abstract: A novel class of therapeutic agents based on nucleic acids has emerged and shown very promising pre-clinical results, named small interfering RNAs (siRNAs) and microRNAs (miRNAs). siRNAs are small RNA duplexes capable of silencing undesired (i.e., mutant, exogenous or aberrant) gene expression with high specificity through a mechanism known as RNA interference. These agents have called special attention to neuroscience since they have been used to experimentally treat a variety of neurological diseases with distinct etiologies such as viral, prions, genetic disorders and others. siRNAs have also been used in other scenarios as: drug-receptor blockage, inhibition of pain signaling and regulation of behavior. Although in a very initial stage, miRNAs also promise novel therapeutic approaches. In this review article we intend to introduce clinicians and researchers to the novel field of si- and miRNA-mediated gene silencing strategies, its history, use in cell and animal models, delivery methods, current status and possible applications in future clinical practice.
Export Options
About this article
Cite this article as:
Pereira Campos Tiago and Lopes-Cendes Iscia, Novel Nucleic Acid-Based Agents: siRNAs and miRNAs, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/187152408784533932
DOI https://dx.doi.org/10.2174/187152408784533932 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Overview of High-grade Glioma: Current and Emerging Treatment Approaches
Current Cancer Therapy Reviews Manipulation and Engineering of Metabolic and Biosynthetic Pathway of Plant Polyphenols
Current Pharmaceutical Design A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology Unraveling the Action Mechanism of Buyang Huanwu Tang (BYHWT) for Cerebral Ischemia by Systematic Pharmacological Methodology
Combinatorial Chemistry & High Throughput Screening Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability
Medicinal Chemistry Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets The Impact of Docosahexaenoic Acid on Alzheimer’s Disease: Is There a Role of the Blood-Brain Barrier?
Current Clinical Pharmacology Identification of Glioma Specific Genes as Diagnostic and Prognostic Markers for Glioma
Current Bioinformatics Nanoscale Functional Biomaterials for Cancer Theranostics
Current Medicinal Chemistry Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued) Formulation, Optimization and Characterization of Bupropion Hydrochloride Loaded Nanostructured Lipid Carriers for Intra-Nasal Administration: An Approach to Management of Smoking Cessation
Current Nanomedicine Recognition Sites for Cancer-targeting Drug Delivery Systems
Current Drug Metabolism Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Current Cancer Therapy Reviews